27339893|t|Structural Basis for Simvastatin Competitive Antagonism of Complement Receptor 3
27339893|a|The complement system is an important part of the innate immune response to infection but may also cause severe complications during inflammation. Small molecule antagonists to complement receptor 3 (CR3) have been widely sought, but a structural basis for their mode of action is not available. We report here on the structure of the human CR3 ligand-binding I domain in complex with simvastatin. Simvastatin targets the metal ion-dependent adhesion site of the open, ligand-binding conformation of the CR3 I domain by direct contact with the chelated Mg(2+) ion. Simvastatin antagonizes I domain binding to the complement fragments iC3b and C3d but not to intercellular adhesion molecule-1. By virtue of the I domain's wide distribution in binding kinetics to ligands, it was possible to identify ligand binding kinetics as discriminator for simvastatin antagonism. In static cellular experiments, 15-25 Î¼m simvastatin reduced adhesion by K562 cells expressing recombinant CR3 and by primary human monocytes, with an endogenous expression of this receptor. Application of force to adhering monocytes potentiated the effects of simvastatin where only a 50-100 nm concentration of the drug reduced the adhesion by 20-40% compared with untreated cells. The ability of simvastatin to target CR3 in its ligand binding - activated conformation is a novel mechanism to explain the known anti-inflammatory effects of this compound, in particular because this CR3 conformation is found in pro-inflammatory environments. Our report points to new designs of CR3 antagonists and opens new perspectives and identifies druggable receptors from characterization of the ligand binding kinetics in the presence of antagonists.
27339893	0	10	Structural	T082	C0678594
27339893	11	16	Basis	T169	C1527178
27339893	21	32	Simvastatin	T109,T121	C0074554
27339893	33	55	Competitive Antagonism	T044	C0013159
27339893	59	80	Complement Receptor 3	T116,T129	C0079785
27339893	85	102	complement system	T116,T129	C0009498
27339893	131	153	innate immune response	T032	C0020969
27339893	157	166	infection	T047	C0009450
27339893	186	206	severe complications	T033	C3495031
27339893	214	226	inflammation	T046	C0021368
27339893	228	242	Small molecule	T109	C1328819
27339893	243	254	antagonists	T120	C0243076
27339893	258	279	complement receptor 3	T116,T129	C0079785
27339893	281	284	CR3	T116,T129	C0079785
27339893	317	327	structural	T082	C0678594
27339893	328	333	basis	T169	C1527178
27339893	344	358	mode of action	T169	C1524059
27339893	380	386	report	T170	C0684224
27339893	399	408	structure	T082	C0678594
27339893	416	421	human	T016	C0086418
27339893	422	425	CR3	T116,T129	C0079785
27339893	426	449	ligand-binding I domain	T087	C0682969
27339893	453	460	complex	T104	C1704241
27339893	466	477	simvastatin	T109,T121	C0074554
27339893	479	490	Simvastatin	T109,T121	C0074554
27339893	491	498	targets	T169	C1521840
27339893	503	508	metal	T197	C0025552
27339893	509	522	ion-dependent	T080	C0205556
27339893	523	536	adhesion site	T082	C1254362
27339893	550	564	ligand-binding	T044	C1517880
27339893	565	577	conformation	T082	C0026377
27339893	585	588	CR3	T116,T129	C0079785
27339893	589	597	I domain	T087	C1514562
27339893	608	620	contact with	T169	C0332158
27339893	625	644	chelated Mg(2+) ion	T109,T121	C0719248
27339893	646	657	Simvastatin	T109,T121	C0074554
27339893	658	669	antagonizes	T033	C0243095
27339893	670	686	I domain binding	T087	C0682969
27339893	694	714	complement fragments	T116,T129	C0009498
27339893	715	719	iC3b	T116,T129,T192	C0369029
27339893	724	727	C3d	T116,T129,T192	C0056184
27339893	739	772	intercellular adhesion molecule-1	T116,T129	C0063695
27339893	777	783	virtue	T078	C0042764
27339893	791	801	I domain's	T087	C1514562
27339893	807	819	distribution	T082	C0037775
27339893	823	839	binding kinetics	T039	C0031327
27339893	843	850	ligands	T103	C0023688
27339893	859	867	possible	T033	C0332149
27339893	880	894	ligand binding	T044	C1517880
27339893	895	903	kinetics	T039	C0031327
27339893	925	936	simvastatin	T109,T121	C0074554
27339893	937	947	antagonism	T044	C0013159
27339893	952	958	static	T080	C0441463
27339893	959	967	cellular	T059	C0178539
27339893	968	979	experiments	T062	C0681814
27339893	990	1001	simvastatin	T109,T121	C0074554
27339893	1002	1009	reduced	T080	C0392756
27339893	1010	1018	adhesion	T067	C3714578
27339893	1022	1032	K562 cells	T025	C0600432
27339893	1033	1043	expressing	T045	C0597360
27339893	1044	1055	recombinant	T001	C1514798
27339893	1056	1059	CR3	T116,T129	C0079785
27339893	1067	1074	primary	T080	C0205225
27339893	1075	1080	human	T016	C0086418
27339893	1081	1090	monocytes	T025	C0026473
27339893	1100	1110	endogenous	T169	C0205227
27339893	1111	1121	expression	T045	C0597360
27339893	1130	1138	receptor	T116,T192	C0597357
27339893	1140	1151	Application	T058	C0185125
27339893	1155	1160	force	T067	C0441722
27339893	1164	1172	adhering	T067	C3714578
27339893	1173	1182	monocytes	T025	C0026473
27339893	1199	1209	effects of	T080	C1704420
27339893	1210	1221	simvastatin	T109,T121	C0074554
27339893	1245	1258	concentration	T081	C1446561
27339893	1266	1270	drug	T121	C1254351
27339893	1271	1278	reduced	T080	C0392756
27339893	1283	1291	adhesion	T067	C3714578
27339893	1302	1310	compared	T052	C1707455
27339893	1316	1325	untreated	T080	C0205556
27339893	1326	1331	cells	T025	C0007634
27339893	1337	1344	ability	T032	C0085732
27339893	1348	1359	simvastatin	T109,T121	C0074554
27339893	1363	1369	target	T169	C1521840
27339893	1370	1373	CR3	T116,T129	C0079785
27339893	1381	1395	ligand binding	T044	C1517880
27339893	1398	1407	activated	T052	C1879547
27339893	1408	1420	conformation	T082	C0026377
27339893	1426	1431	novel	T080	C0205314
27339893	1432	1441	mechanism	T044	C0678659
27339893	1463	1488	anti-inflammatory effects	T080	C1515999
27339893	1497	1505	compound	T103	C1706082
27339893	1534	1537	CR3	T116,T129	C0079785
27339893	1538	1550	conformation	T082	C0026377
27339893	1563	1579	pro-inflammatory	T080	C0205556
27339893	1580	1592	environments	T082	C0014406
27339893	1598	1604	report	T170	C0684224
27339893	1619	1626	designs	T090	C0013171
27339893	1630	1633	CR3	T116,T129	C0079785
27339893	1634	1645	antagonists	T120	C0243076
27339893	1677	1687	identifies	T033	C0243095
27339893	1688	1697	druggable	T080	C0205556
27339893	1698	1707	receptors	T116,T192	C0597357
27339893	1713	1729	characterization	T052	C1880022
27339893	1737	1751	ligand binding	T044	C1517880
27339893	1752	1760	kinetics	T039	C0031327
27339893	1768	1776	presence	T080	C3854307
27339893	1780	1791	antagonists	T120	C0243076